What Are The 4 Stages Of Prostate Cancer?

When diagnosed with prostate cancer, your treatment options and prognosis are determined by how advanced the cancer is at that time. Healthcare providers rely on the TNM staging system and the Gleason grading scale to evaluate the impact of the cancer on the prostate and to assess its spread. Below is an overview of how prostate cancer staging and grading operate.

How Prostate Cancer Advances and Spreads

Prostate cancer typically develops slowly within the prostate gland, often remaining localized for a significant period. However, as time progresses, it can spread beyond the prostate in several ways:

• Invasion: The cancerous cells grow into and infiltrate nearby tissues.
• Lymphatic Spread: Cancer cells travel through the network of lymph nodes and lymph vessels.
• Metastasis: Cancer spreads to distant tissues and organs via the bloodstream.

The staging of prostate cancer indicates the extent to which the disease has progressed and spread.

Methods to Determine the Stage of Prostate Cancer

Once diagnosed with prostate cancer, your doctor will conduct specific tests to determine how far the disease has progressed. Not all men require every available test; the selection depends on the results of your prostate biopsy, a procedure that examines prostate tissue for signs of cancer. Common tests used to assess the stage of prostate cancer include:

• Digital Rectal Exam (DRE)
• PSA (Prostate-Specific Antigen) Test
• Transrectal Ultrasound
• MRI Scan of the Prostate
• CT Scan of the Abdomen and Pelvis – Helps identify if the cancer has spread to surrounding areas.
• Nuclear Medicine Bone Scan – Detects whether the cancer has reached the bones.
• Pelvic Lymph Node Surgery – Evaluates lymph nodes in the pelvic region for potential cancer spread.

These tests provide critical information, guiding your doctor in creating an effective treatment plan.

Understanding Prostate Cancer Grading

Cancer cells differ significantly from healthy cells. The greater the difference, the more aggressive the cancer typically is.

The Gleason Grading System evaluates these differences, assigning numbers from 1 to 5 to describe the primary (most common) and secondary (second most common) patterns of cancer cells in a tissue sample.

• Grade 1: Cells closely resemble normal prostate cells.
• Grades 2 to 4: Lower scores indicate cells that are closer to normal, associated with less aggressive cancer. Higher scores show cells that deviate more from normal, suggesting faster growth and greater aggressiveness.
• Grade 5: The majority of cells appear very abnormal and differ significantly from healthy cells.

Understanding Your Gleason Score: What It Means for Cancer Aggression

Medical professionals calculate your total Gleason score by combining your primary and secondary numbers. This score helps determine how aggressive the cancer is. A score of 6 represents low-grade cancer, indicating less aggressive behavior. A Gleason score of 7 signifies medium-grade cancer, while scores of 8, 9, or 10 indicate high-grade cancer, which is more aggressive.

In general, a higher Gleason score corresponds to a more aggressive form of cancer, increasing the likelihood of growth and spread to other areas of the body. Doctors rely on this score, alongside the cancer’s stage, to develop the most effective treatment plan tailored to your condition.

Understanding the TNM System for Prostate Cancer Staging

Healthcare professionals rely on the TNM system to classify and stage prostate cancer, as they do with many other types of cancer. This framework evaluates three critical factors related to tumor development and spread:

Tumor (T): What is the size and extent of primary prostate cancer?
Nodes (N): Has the cancer reached the lymph nodes? If yes, how extensively and to how many nodes?
Metastasis (M): How far has prostate cancer advanced to other parts of the body?

Stages of Prostate Cancer

Prostate cancer staging involves combining T, N, and M classifications with the Gleason score and PSA level in a process known as stage grouping. This system categorizes the disease using Roman numerals, from I (early stage) to IV (advanced stage). Understanding the stage helps your doctor determine the most effective treatment plan.

Stage I

At this stage, the cancer is confined to the prostate and hasn’t spread beyond it:

• The tumor is usually undetectable during a digital rectal exam (DRE) or imaging tests.
• The Gleason score is 6 or lower, and PSA levels are under 10.
• The tumor affects half or less of one side of the prostate.

Stage IIA

The cancer remains localized within the prostate:

• It may or may not be detected during a DRE or on imaging tests.
• The tumor might involve more than half of one lobe but does not extend to both lobes.
• The Gleason score is 7 or lower, with PSA levels under 20.

Stage IIB

The cancer stays within the prostate but could be more widespread:

• It may or may not be detectable during a DRE or imaging tests.
• The tumor may affect one or both lobes of the prostate.
• The Gleason score is 7, and PSA levels are under 20.

Stage IIC

At this stage, the cancer has not spread beyond the prostate:

• It may or may not be visible on imaging or palpable during a DRE.
• The tumor might involve one or both lobes.
• The Gleason score is 7 or 8, with PSA levels under 20.
• The cancer cells show more abnormal characteristics compared to Stage IIB.

Stage IIIA

The cancer is still confined to the prostate, with no lymph node involvement:

• It may or may not be detected during a DRE or imaging.
• The Gleason score is 8 or lower, but PSA levels are 20 or higher.

Stage IIIB

The cancer has grown beyond the prostate but has not spread to the lymph nodes or distant areas:

• The Gleason score is 8 or lower, and PSA levels can be at any value.

Stage IIIC

The cancer may or may not have spread outside the prostate but hasn’t reached the lymph nodes:

• The Gleason score is 9 or 10, and PSA levels can vary.

Stage IVA

In this stage, the cancer:

• May or may not have spread to tissues near the prostate.
• Has spread to nearby lymph nodes but not to distant parts of the body.
• Can have any Gleason score and PSA level.

For stages I to IVA, the 5-year relative survival rate is nearly 100%. This high survival rate reflects the importance of early detection, as the majority of prostate cancers are diagnosed at these stages.

Stage IVB

The cancer has reached distant parts of the body, such as bones, lymph nodes, or other organs:

• It may or may not have spread to nearby tissues or lymph nodes.
• The Gleason score and PSA levels can be of any value.

Accurate staging is critical, as it influences both treatment choices and overall prognosis. Extensive testing ensures the cancer stage is correctly identified. For advanced cases where the cancer has spread to distant areas like the lungs, liver, or bones, the 5-year relative survival rate drops to 30%. While survival statistics provide insight into treatment success rates, they cannot predict individual outcomes.

Other Test Results

In some cases, prostate cells may appear abnormal without being definitively cancerous. These findings are commonly labeled as “suspicious” and categorized into two main groups: atypical or prostatic intraepithelial neoplasia (PIN).

Prostatic intraepithelial neoplasia (PIN) is further classified into low-grade and high-grade types. The connection between low-grade PIN and prostate cancer remains uncertain. It is common for younger men to develop low-grade PIN without ever progressing to prostate cancer.

However, biopsy findings indicating atypical cells or high-grade PIN suggest a higher likelihood of prostate cancer being present elsewhere in the prostate. When high-grade PIN is detected, there is a 30% to 50% probability of identifying prostate cancer in subsequent biopsies. As a result, doctors typically recommend additional biopsies to monitor for potential cancer development.

Conclusion

Prostate cancer is a complex disease with varying levels of severity based on its stage and grade. The 4 stages of prostate cancer, from Stage I to Stage IVB, outline its progression from being localized within the prostate to spreading to distant parts of the body. Early detection through diagnostic methods like PSA tests, imaging, and biopsies plays a critical role in ensuring effective treatment and improving survival rates. Tools like the Gleason grading system and the TNM staging framework offer healthcare providers detailed insights into the cancer’s aggressiveness and spread.

While survival rates are promising for early-stage prostate cancer, advanced stages present greater challenges. Understanding the disease’s progression and working closely with healthcare professionals to monitor and manage its development is crucial. By staying informed and proactive, patients can better navigate the journey of prostate cancer, from diagnosis to treatment and beyond.

FAQs

What are the 4 stages of prostate cancer?

Prostate cancer is divided into four stages:

• Stage I: The cancer is confined to the prostate and not detectable through imaging.
• Stage II: The cancer remains localized but is more prominent and may involve one or both lobes of the prostate.
• Stage III: The cancer begins to spread beyond the prostate but hasn’t reached distant organs.
• Stage IV: The cancer has spread to lymph nodes (Stage IVA) or distant organs like bones or the liver (Stage IVB).

What is the Gleason score, and why is it important?

The Gleason score assesses the aggressiveness of prostate cancer by evaluating the difference between cancer cells and normal cells. Scores range from 6 (low-grade) to 10 (high-grade), with higher scores indicating more aggressive cancer. It helps doctors predict the cancer’s behavior and tailor treatment plans.

How is prostate cancer detected?

Prostate cancer is detected using several methods, including:

• PSA (Prostate-Specific Antigen) blood tests.
• Digital Rectal Exam (DRE).
• Imaging techniques like MRI and CT scans.
• A prostate biopsy, which examines tissue samples for cancer cells.

Can prostate cancer be cured?

Prostate cancer is highly treatable, especially in the early stages. Treatment options include surgery, radiation therapy, hormone therapy, and active surveillance. The success of treatment depends on factors such as the stage of cancer, Gleason score, and the patient’s overall health.

What is the survival rate for prostate cancer?

The survival rate varies based on the stage:

• For localized and regional stages (I to IVA), the 5-year relative survival rate is nearly 100%.

For Stage IVB, where cancer has spread to distant organs, the 5-year relative survival rate drops to about 30%. Early detection significantly improves outcomes.